Renal Proximal Tubular Reabsorption Is Reduced In Adult Spontaneously Hypertensive Rats
Roles of Superoxide and Na⁺/H⁺ Exchanger 3

Carolina Panico, Zaiming Luo, Sara Damiano, Francesca Artigiano, Pritmohinder Gill, William J. Welch

Abstract—Proximal tubule reabsorption is regulated by systemic and intrinsic mechanisms, including locally produced autacoids. Superoxide, produced by NADPH oxidase enhances NaCl transport in the loop of Henle and the collecting duct, but its role in the proximal tubule is unclear. We measured proximal tubule fluid reabsorption (Jv) in WKY rats and compared that with Jv in the spontaneously hypertensive rat (SHR), a model of enhanced renal superoxide generation. Rats were treated with the NADPH oxidase inhibitor apocynin (Apo) or with small interfering RNA for p22(phox), which is the critical subunit of NADPH oxidase. Jv was lower in SHR compared with Wistar-Kyoto rats (WKY; WKY: 2.3±0.3 vs SHR: 1.1±0.2 nL/min per millimeter; n=9 to 11; P<0.001). Apo and small interfering RNA to p22(phox) normalized Jv in SHRs but had no effect in WKY rats. Jv was reduced in proximal tubules perfused with S-1611, a highly selective inhibitor of the Na+/H+ exchanger 3, the major Na+ uptake pathway in the proximal tubule, in WKY rats but not in SHRs. Pretreatment with Apo restored an effect of S-1611 to reduce Jv in the SHRs (SHR+Apo: 2.9±0.4 vs SHR+Apo+S-1611: 1.0±0.3 nL/min per millimeter; P<0.001). However, because expression of the Na+/H+ exchanger 3 was similar between SHR and WKY rats, this suggests that superoxide affects Na+/H+ exchanger 3 activity. Direct microperfusion of Tempol or Apo into the proximal tubule also restored Jv in SHRs. In conclusion, superoxide generated by NADPH oxidase inhibits proximal tubule fluid reabsorption in SHRs. This finding implies that proximal tubule fluid reabsorption is regulated by redox balance, which may have profound effects on ion and fluid homeostasis in the hypertensive kidney. (Hypertension. 2009;54:1291-1297.)

Key Words: proximal reabsorption ▪ superoxide ▪ Tempol ▪ apocynin ▪ hypertension

In the kidney, the proximal tubule (PT) reabsorbs 60% to 70% of filtered NaCl and fluid. Therefore, changes in PT reabsorption can have profound effects on renal and body fluid balance and may contribute to the development of hypertension. The normal kidney protects against acute increases in blood pressure by excreting NaCl rapidly. The PT is thought to mediate much of this pressure-natriuresis response. In young spontaneously hypertensive rats (SHRs), before the onset of hypertension, expression of the major Na+ transport systems in the PTs was higher and Na+ excretion was lower compared with normotensive rats (Wistar-Kyoto [WKY]). This was accompanied by an increase in fluid reabsorption in the PT in young (5-week-old) prehypertensive SHRs compared with WKY. These observations suggest that an exaggerated NaCl and fluid reabsorption in the PT may contribute to the development of hypertension in young SHRs, which persists in the adult animal. However, the increased reabsorption seen in young animals is not consistently observed in adult SHRs. For example, in 7- and 12-week-old SHRs, at a time when hypertension was established, baseline proximal tubule fluid reabsorption (Jv) in the PT was lower compared with that in WKY rats. Jv was also lower in adult stroke-prone SHRs compared with WKY rats. This may be related to increased reactive oxygen species, because direct microperfusion of reducing agents corrected this dysfunction. The SHR is indeed an established model of oxidative stress, with elevated superoxide levels and NADPH oxidase (NOX) expression in both vascular and renal tissue.

The uncertain role of the PT is partially attributed to the difficult technologies in measuring function. PT transport in SHRs has been investigated primarily in vitro with cell preparations or in vivo by free-flow micropuncture. However, free-flow measurements, which have characterized PT function on both WKY rats and SHRs, are complicated by the interruption of flow to the macula densa, which tends to overestimate PT flow. Therefore, direct measurement of Jv by in situ microperfusion is the most accurate method to characterize PT function, because this method separates transport from the confounding effects of flow and tubuloglomerular feedback. Therefore, we measured Jv in the PTs of hyperten-
sive and normotensive rats by direct microperfusion and recollection to test the hypothesis that increased production of superoxide \((\text{O}_2^-)\) impairs PT function during hypertension in the adult SHR.

**Materials and Methods**

**Animal Preparation**

Groups of SHRs and aged-matched WKY rats were pretreated with apocynin (Apo; 16 mg/kg per day), small interfering RNA (siRNA; 25 \(\mu\)g, IV) or vehicle (IV) 2 days before experimentation. The Georgetown Animal Care and Use Committee approved the use of rats in this study. On day 3, animals were anesthetized with thiobarbitual (Inactin, 80 g/kg IP; Research Biochemicals, Inc) and prepared for in vivo micropuncture studies. Cannulae were placed in a jugular vein for infusion of fluids and in a femoral artery for the recording of mean arterial pressure (MAP: Powerlab, AD Instruments Inc). A tracheotomy tube was inserted. The animals were allowed to breathe room air spontaneously. A catheter was inserted in the bladder and another in the left ureter to collect urine. The left kidney was exposed by a flank incision and stabilized in a Lucite cup (Vestavia) mounted on a heated surgical table and bathed in mineral oil maintained at \(37^\circ\text{C}\). After surgical preparation, rats were infused with a solution of 0.154 mol/L of NaCl and 1% albumin at 1.5 mL/h with a solution of 0.154 mol/L of NaCl and 1% albumin at 1.5 mL/h to maintain euvoemuia. \(^8\) Studies were begun after 60 minutes of stabilization.

**Microperfusion of PTs**

The PT site was identified, as described previously. \(^7\) by injections from a “finding” pipette containing dye-stained artificial tubular fluid. The flow was blocked by injection of \(T\) grease (T grade, Apiezon Products) via a micropipette (10 to 12 \(\mu\)m OD) proximal to the perfusion site. The tubule was perfused with a micropipette (8 to 10 \(\mu\)m OD) connected to a microperfusion pump (model A1400, World Precision Instruments Inc) at 18±3 mL/min. The perfusion solution contained \(^{13}\text{C}\) inulin (New England Nuclear) as volume marker and 0.1% FD&C green dye for identification of the perfused loops. Tubules were perfused for 2 to 8 minutes before fluid collections, which were made at a downstream site with a micropipette (7 to 10 \(\mu\)m OD) after placement of a column of oil to block downstream flow. Samples were collected for 3 to 5 minutes and transferred into a constant-bore capillary tube for which the length was measured with a micrometer to calculate the tubular fluid volume. \(^7\) Thereafter, the samples were injected into scintillation fluid and the \(^{14}\text{C}\) activity counted. Collected samples with \(<95\%\) and \(>105\%\) of microperfused inulin were discarded. The amount of microperfused inulin was estimated by the average of \(^{14}\text{C}\)-activity in 4 samples microperfused directly into capillary bore tubes at the end of the experiment. To determine the lengths of the perfused segments, tubules were filled with high-viscosity microfil (Flow Tech, Inc). At the end of the experiments, the kidney was partially digested in 20% NaOH, and the casts were measured under a dissecting microscope. The \(J_v\) was calculated by the difference in the perfusion rate and the collection rate factored by the length of the nephron: \(J_v = V_{\text{perf}} - V_{\text{coll}}\) (nanoliters per minute)/PT length (millimeters) where \(V_{\text{perf}}\) indicates perfusion rate and \(V_{\text{coll}}\) indicates collection rate and expressed as nanoliters per minute per millimeter. The composition of the perfusion fluid was as follows in mM: 125 NaCl, 20 NaHCO\(_3\), 5 KCl, 1 MgSO\(_4\), 2 CaCl\(_2\), 1 NaHPO\(_4\), 5 glucose, and 4 urea. In the in vivo nephron microperfusion technique allows for the control of flow rate, Na\(^+\) concentration, osmolality, and extracellular pH. This method is limited by the lack of endogenous agents generated in the PT, because all of the perfusions are with artificial tubular fluid containing various antagonists, but it more directly measures the intrinsic transport properties of the epithelium and allows for the use of various inhibitors to test the roles of key players in the regulation of PT function.

In separate nephrons, proximal and distal tubule flows were measured by free-flow micropuncture collections. In these nephrons, a collecting pipette was inserted into a midproximal or distal tubule, and a small volume of mineral oil was inserted. The oil was allowed to move downstream, and tubular fluid was aspirated into the collection pipette for 3 to 4 minutes. The fluid was transferred to a capillary bore tube and measured by microscopic calibration.

**Small Interference RNA**

The siRNA to rat \(p22^{phox}\) (NM-024160) was validated in vitro, as reported previously. \(^3\) The target site in \(p22^{phox}\) cDNA of the constructs selected is 299 to 320 (AAATTACTAGTCGCCGGGCTGT). The nonsilencing control siRNA sequence ATTTCGCGAACGTGTCACGC (catalogue No. 1022076; Qiagen) has no homology to any sequence in the mammalian genome. TransIT In-Vivo gene delivery system (Mirus) was used to complex the \(p22^{phox}\) siRNA to polymer as per the manufacturer’s recommendations. This complexed siRNA was brought to 6-mL volume and delivered via the jugular vein in 7 seconds. Kidney cortex was harvested after 48 hours and saved for gene analysis. In a separate group of SHRs, PTs were microdissected for the measurement of mRNA.

**Microdissection of PTs**

The kidneys were perfused through the abdominal aorta with 10 mL of cold solution dissection to rinse away the blood. The composition of the dissection solution was as follows, in mM: 135.0 NaCl, 50 KCl, 1.0 NaH\(_2\)PO\(_4\), 1.2 MgSO\(_4\), 2.0 CaCl\(_2\), 6.0 l-alanine, 10.0 hydroxyethylpiperazine-N\(^\prime\)-2-ethanesulfonic acid, and 5.5 glucose, as well as 0.1% BSA. The kidneys were then perfused with 10 mL of cold dissection solution containing 0.1% collagenase (CLS II, Worthington). Thin sagittal sections were cut from the perfused kidneys and incubated in dissection solution containing 0.1% collagenase at \(37^\circ\text{C}\) for 30 minutes during which the solution was bubbled with 100% oxygen. Microdissection of individual PT segments was performed in cold dissection solution under a stereomicroscope. \(^10\)

**RNA Extraction, cDNA Synthesis, and Real-Time PCR**

The kidney cortex and PTs were harvested after 48 hours, and RNA was extracted using an RNAsqueous-4PCR kit (Ambion). The cDNA was synthesized using superscript III with a random hexamer (Invitrogen). The gene expression for \(p22^{phox}\) was assessed with real-time PCR (ABI 7700), using a FAM (6-carboxy-fluorescence dye)-labeled \(p22^{phox}\) Taqman probe assay (Rn00577357_m1, ABI) multiplexed with a VIC (fluorescence dye)-labeled 18S control probe. Relative amounts of mRNA, normalized by 18S rRNA, were calculated from threshold cycle numbers (\(C_T\), ie, \(2^{-\Delta\Delta C_T}\)).

**SDS-PAGE Gel Electrophoresis and Western Analysis**

SDS-PAGE Gel Electrophoresis and Western Analysis

The kidney cortex was placed in radioimmunoprecipitation assay lysis buffer containing the following protease inhibitors: 100 \(\mu\)g/mL of PMSF, 5 \(\mu\)g/mL of leupeptin, 5 \(\mu\)g/mL of aprotinin, and 1 mmol/L of sodium fluoride per milliliter. The dissected sections with radioimmunoprecipitation assay lysis buffer were homogenized in FastPrep Bio101 (Thermo), and the tubes were spun at 12 500 rpm for 15 minutes in a cold centrifuge. The supernatant was aliquoted and frozen at \(-80^\circ\text{C}\) for future analysis. Protein concentrations were determined by Bio-Rad Protein Assay Reagent (Bio-Rad). Protein lysate (100 \(\mu\)g) for each sample was denatured in boiling water for 5 minutes. After denaturation, the lysate was placed on ice for 5 minutes and loaded onto a 12.5% SDS-PAGE gel (Bio-Rad). The gel was transferred to nitrocellulose membrane (Bio-Rad). The membrane was blocked with 5% Blotto milk. The primary antibody for 2 \(C_{\text{II}}\). The control siRNA was as follows: TGG TGT CAA TAA GCT TGC TGC T (catalogue No. 1022076; Qiagen) has no homology to any sequence in the mammalian genome. TransIT In-Vivo gene delivery system (Mirus) was used to complex the \(p22^{phox}\) siRNA to polymer as per the manufacturer’s recommendations. This complexed siRNA was brought to 6-mL volume and delivered via the jugular vein in 7 seconds. Kidney cortex was harvested after 48 hours and saved for gene analysis. In a separate group of SHRs, PTs were microdissected for the measurement of mRNA. The kidneys were then perfused with 10 mL of cold dissection solution containing 0.1% collagenase (CLS II, Worthington). Thin sagittal sections were cut from the perfused kidneys and incubated in dissection solution containing 0.1% collagenase at \(37^\circ\text{C}\) for 30 minutes during which the solution was bubbled with 100% oxygen. Microdissection of individual PT segments was performed in cold dissection solution under a stereomicroscope. \(^{10}\)
Table. MAP and Renal Parameters

<table>
<thead>
<tr>
<th>Variable</th>
<th>MAP, mm Hg</th>
<th>GFR, mL/min</th>
<th>VPT, nL/min</th>
<th>VDT, nL/min</th>
<th>UV, µL/min</th>
</tr>
</thead>
<tbody>
<tr>
<td>WKY (n=6 to 10)</td>
<td>100±5</td>
<td>1.9±0.3</td>
<td>13.9±0.9</td>
<td>6.5±1.2</td>
<td>4.6±0.2</td>
</tr>
<tr>
<td>SHR (n=6 to 9)</td>
<td>185±6*</td>
<td>1.7±0.5</td>
<td>12.2±0.9</td>
<td>5.9±0.8</td>
<td>4.4±0.5</td>
</tr>
<tr>
<td>WKY+Apo (n=4 to 7)</td>
<td>95±3</td>
<td>2.3±0.6</td>
<td>13.3±0.5</td>
<td>5.5±0.8</td>
<td>4.0±0.3</td>
</tr>
<tr>
<td>SHR+Apo (n=4 to 7)</td>
<td>190±6*</td>
<td>2.0±0.5</td>
<td>8.3±0.5*</td>
<td>5.3±0.3</td>
<td>4.5±0.5</td>
</tr>
</tbody>
</table>

GFR indicates glomerular filtration rate; VPT, proximal tubule flow; VDT, distal tubule flow; UV, urine flow. Each parameter was analyzed by 2×2 ANOVA.

Results

MAP measured under anesthesia was higher in SHRs compared with WKY rats (Table). Treatment for 2 days with Apo had no effect on MAP in either strain. Proximal flow, measured by free-flow collections in separate nephrons, was similar between WKY rats and SHRs but was decreased by Apo in SHRs only (P<0.001). Distal flow and urine flow were similar in all of the groups.

Protocol 1
First, absolute fluid reabsorption (Jv) measured in the PT averaged 2.3±0.3 nL/min in normotensive WKY rats (Figure 1). However, Jv was lower in PTs of SHRs (1.1±0.2 nL/min per millimeter; P<0.001). Apo, an inhibitor of NOX, had no effect on Jv in WKY rats but restored Jv to normal levels in SHRs.

Second, in a separate SHR group, renal perfusion pressure was maintained at 122±6 mm Hg by an aortic clamp (SHR+clamp). Jv was unaffected by the acute reduction in renal perfusion pressure (SHR: 1.1±0.2 vs SHR+clamp: 1.3±0.3 nL/min per millimeter; n=6 to 7; P value not significant). This suggests that the differences in Jv between the 2 strains were not directly related to MAP.

Third, Figure 2 shows that the protein expression of NHE3 in the renal cortex was similar in SHRs compared with WKY rats. NHE3 in the renal cortex is exclusively expressed in the PT. NHERF2 is a postsynaptic density protein-95-disc large- 

zonula occludens-1 domain-binding element that is associated with reduced NHE-3 activity and translocation. NHERF2 expression in the renal cortex was higher in SHRs compared with WKY rats (Figure 2), suggesting that reduced NHE3 activity in SHRs is attributed to overexpression of this regulatory factor. Indeed, NHERF-2 expression in SHRs was reduced by Apo, further implicating this pathway in NHE3 dysregulation in SHRs.

Figure 3 shows that direct microperfusion of Tempol (10^-4 M) also restored Jv in SHRs (WKY: 2.3±0.5 vs SHRs: 2.4±0.5 nL/min per millimeter, P<0.001). Similarly, acute microperfusion of Apo (10^-5 M) also restored Jv in SHRs (SHR: 1.2±0.3 vs SHR+Apo: 2.0±0.3 nL/min per millimeter; P<0.05; n=8).

Protocol 2
To determine the mechanism of this dysfunction, we tested the activity of NHE3, a major Na^+ uptake path in the PT. Jv
was reduced by direct microperfusion of the NHE3 selective inhibitor, S-1611 (10^{-5} M, maximally effective dose) in WKY rats as expected, but not in SHRs (Figure 4). This suggests that the dysfunction is attributable to the reduction in NHE3 activity. When the reduced Jv of SHRs was restored by Apo, direct microperfusion of S-1611 lowered Jv, similar to its effect in WKY rats (Figure 5). This suggests that the dysfunction of NHE3 is linked to NOX–generated O_{2}^{-}.

### Protocol 3

To confirm that the reduction in Jv of the PT was linked to NOX, we repeated these experiments in rats treated with siRNA direct to p22phox, the critical subunit of NOX. mRNA expression of p22phox, relative to expression of 18S, was reduced by siRNA treatment by 62±4% (n=6) in the renal cortical tissue and by 65±7% in microdissected PTs (n=4; Figure 6). Jv in SHRs was restored by siRNA to p22phox but unaffected in WKY rats (Figure 7). MAP was not affected by siRNA to p22phox (MAP scr siRNA: 118±3 mm Hg; MAP p22phox: 115±3 mm Hg; P value not significant).

**Discussion**

The major new finding of this study is that fluid reabsorption in the PT of adult SHRs is impaired compared with that in WKY rats. In addition, this reduced function can be completely restored by inhibition of O_{2}^{-}. Treatments that targeted O_{2}^{-} in general (Tempol) and the more specific source of O_{2}^{-}, NOX (Apo, siRNA), restored the lower Jv of the PT in SHRs. Two results suggest that these effects are independent of the high blood pressure in SHRs. First, Apo and siRNA to p22phox did not lower BP in SHRs, yet Jv was corrected. Second, clamping of the renal artery in SHRs to reduce renal perfusion pressure to normotensive levels had no effect on the reduced Jv.

To evaluate the mechanism of the reduced Jv, PTs were perfused with S-1611, a highly selective inhibitor of NHE3. S-1611 reduced Jv in WKY PT by 50% but, surprisingly, had no effect on the reduced Jv in SHRs. However, when Jv was restored in SHR nephrons with Apo, subsequent microperfusion of S-1611 reduced Jv by 50%, similar to its effect in WKY rats. Because there was no difference in the expression of NHE3 in the renal cortex between strains, these data suggest that the difference in Jv between SHRs and WKY rats is linked to NHE3 activity rather than content. NHE3 activity may depend on the NHERFs. We showed that NHERF2 expression was higher in SHRs than WKY rats, which may account for reduced NHE3 activity in SHRs. In addition, Apo reduced NHERF2 expression, consistent with restoration of PT function. However, both Apo and Tempol microperfused acutely into the PT restored Jv in SHRs. This suggests that O_{2}^{-} also regulates Jv directly and perhaps independently of NHE3 and NHERF2. Combined, these results suggest that Jv is regulated by a complex interaction of regulatory factors (NHERF2), which translocates NHE3, and more acutely by O_{2}^{-} inactivation of NHE3. The acute effect of O_{2}^{-} may not
be because of translocation of NHE3, but further studies will be required to determine this mechanism.

Young SHRs have an enhanced proximal tubular reabsorption and sodium uptake, based on reports of greater NHE3 activity and lower Na\(^+\) excretion. Also, \(J_v\) measured by split-drop micropuncture, which measures the time of injected fluid uptake in the PT, was also higher in 5-week-old SHRs. These studies have popularized the concept that Na\(^+\) retention in young SHRs contributes to the development of hypertension. However, this overactive PT does not persist into adulthood. The reduced \(J_v\) in the PT of SHRs in this study contrasts with the findings in other studies that did not detect differences in PT flow or reabsorption between adult SHRs and WKY rats. In fact, many studies do not report differences in Na\(^+\) excretion or transporter activities between adult SHRs and normotensive rats. However, direct measurements have shown that \(J_v\) is lower in adult hypertensive rats compared with normotensive rats. Therefore, our observations with microperfusion and recollection in the SHR confirm these earlier studies that used the split-drop methodology. In addition, Wu and Johns showed that the reduced \(J_v\) could be restored by local delivery of exogenous O\(_2^–\) dismutase. We confirmed this observation using the membrane-permeant antioxidant Tempol and Apo. In addition, we have extended the studies on the role of O\(_2^–\) in regulation of PT function by NHE3 and NHERF2 expression.

As noted above, PT flow was similar in SHRs compared with normotensive rats. Indeed, we also failed to see differences in PT flow between WKY rats and SHRs when measured by free-flow collections in separate nephrons (Table). However, when O\(_2^–\) was suppressed by Apo, PT flow was substantially reduced in the SHR PT, consistent with increased \(J_v\) in this group. The failure to detect basal differences in PT flow in hypertension remains unclear. This could be because of the method used in this study, which blocks flow to the macula densa and tends to increase glomerular filtration rate and, therefore, PT flows in both strains. In addition, similar flow in this segment could be real, and the differences in transport function between these strains occur in segments not evaluated in this study.

How is the PT regulated by O\(_2^–\)? One possibility is the interaction of O\(_2^–\) and NO. NO inhibits Na\(^+\) uptake in the thick ascending loop of Henle via its effects on cGMP and on the density of membrane channels. However, NO promotes Na\(^+\) and/or fluid reabsorption in the PT. \(J_v\), measured by the same method in this study, was lower in inducible NO synthase (NOS) and neuronal NOS knockout mice. \(J_v\) in normal rat PT is also reduced by NOS inhibition. Taken together, these results suggest that endogenous NO enhances fluid transport in the PT. Therefore, O\(_2^–\), which reduces bioavailable NO, should inhibit fluid reabsorption in the PT, which is consistent with our finding. However, NOS expression in the PT is not consistently shown; therefore, the source of NO is not known. However, there is considerable evidence that PT is constantly exposed to NO, because NOS is expressed in adjacent tissue and cells. In the kidney, endothelial NOS is expressed predominantly in the renal vascular endothelial cells. Also, neuronal NOS is expressed in the epithelium, Bowman’s capsule, and especially in the macula densa, which is in close contact with the PT in the renal cortex. Inducible NOS is widely expressed in the tubule epithelium, including the PT, the thick ascending limb of Henle’s loop, and the distal convoluted tubule. Data supporting the effects of NO to enhance Na\(^+\) uptake are difficult to obtain, because systemic administration of NOS inhibitors increases blood pressure and renal perfusion pres-

![Figure 4](http://hyper.ahajournals.org/)

**Figure 4.** \(J_v\) in PT of WKY rats (n=8) and SHRs (n=7): effects of PT microperfusion of the NHE3 inhibitor, S-1611.

![Figure 5](http://hyper.ahajournals.org/)

**Figure 5.** \(J_v\) in WKY rats (n=9) and SHRs (n=7) after Apo: effects of microperfusion of the NHE3 inhibitor, S-1611.
swe.25–27 However, an acute dose of an inducible NOS inhibitor, but not a neuronal NOS inhibitor, both of which did not increase MAP, increased Na⁺ excretion 2-fold in rats.28 Also, we showed that microperfusion of the PT with a nonselective NOS inhibitor reduced Jv by 30% to 40%, suggesting that NO promotes Na⁺ uptake in the PT.17

Another possibility suggested by our data is that O₂⁻ inhibits NHE3 activity. NHE3 is a major Na⁺ uptake mechanism in the PT, and increased activity of NHE3 in the renal brush border membrane may be involved in the pathogenesis of hypertension.29–32 However, in elegant experiments, Yip et al33 and Sneddon et al34 showed that NHE3 is inactivated by translocation. Therefore, reduced reabsorption in PT of SHRs may be attributed to a relocation of the NHE3, which would alter function.34,35 We showed that, in the SHR, NHE3 activity is suppressed and can be restored by several strategies. Therefore, it is possible that high renal levels of O₂⁻ lead to translocation of NHE3, and antioxidants reactivate this pathway. In addition, the regulatory factor for NHE3, NHERF2, may participate in the redox regulation of NHE3. Increased NHERF2 leads to translocation and inactivation of NHE3.36,37 We confirmed that NHERF2 is higher in the SHR.38 This increase is because of higher levels of O₂⁻, because Apo reduced NHERF2 levels and increased NHE3 expression in the renal cortex and improved Jv in the PT in the SHR.

Renal levels of O₂⁻ and NOX are higher in SHRs compared with WKY rats.39,40 In addition, in this study we show that p22phox mRNA is expressed in microdissected PTs and is reduced by systemic infusion of siRNA to p22phox. Also, direct microperfusion of Tempol and Apo into the PT suggests that the increased O₂⁻ in the SHR is derived from NOX in the PT. Consistent with this view, we showed that the SHR kidneys also had greater expression of NOS, yet bioavailable NO was lower in SHRs.41 Treatment with Tempol increased NO function and presumably NO levels, indicating the powerful scavenging effects of O₂⁻.

Additional explanation of these results is required, because Na⁺ and fluid excretion of age-matched SHRs and WKY rats are similar.12 We suggest that downstream sites of Na⁺ reabsorption are increased by O₂⁻, which compensates for the dysfunction in the PT. Ortiz and Garvin13 have shown that O₂⁻ increased Na⁺ reabsorption in the thick ascending loop of Henle and the collecting duct, which could normalize excretion. The shift in nephron relative function can potentially alter oxygen consumption, because the PT is more O₂ efficient for Na⁺ transport than downstream segments. Therefore, the increased O₂⁻ in SHRs may contribute to the reduced oxygen efficiency and renal hypoxia seen in this strain.40

In conclusion, fluid uptake in the PT of adult SHRs is impaired because of increased NOX-dependent O₂⁻. Our data suggest that O₂⁻ reduces NHE3 activity, possibly because of increased expression of the NHE3 regulatory factor, but also inhibits fluid uptake independent of these pathways. These data suggest that increased reactive oxygen species alters proximal tubular reabsorption during hypertension and impacts renal regulation of fluid and solute balance.

**Perspectives**

These data suggest that, during hypertension, responsibility for Na⁺ and fluid reabsorption along the nephron changes. Reabsorption in the PT is reduced and is increased downstream. This has an impact on oxygen usage for Na⁺ uptake, because the PT is relatively more efficient than more distal segments. Therefore, to preserve normal Na⁺ excretion, the kidney burns more oxygen as it transfers work during a chronic increase in blood pressure. This may be a normal adaptation as the kidney acts to maintain stable Na⁺ balance. Increased O₂⁻ generated during hypertension mediates this shift and, therefore, may be an adaptive process that allows the kidney to preserve normal function at the expense of more oxygen usage.

**Sources of Funding**

The studies reported in this article were supported by the National Institutes of Health grants HL089583 and DK072183.
Disclosures

None.

References

Renal Proximal Tubular Reabsorption Is Reduced In Adult Spontaneously Hypertensive Rats: Roles of Superoxide and Na+/H+ Exchanger 3
Carolina Panico, Zaiming Luo, Sara Damiano, Francesca Artigiano, Pritmohinder Gill and William J. Welch

Hypertension. 2009;54:1291-1297; originally published online October 5, 2009;
doi: 10.1161/HYPERTENSIONAHA.109.134783
Hypertension is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2009 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://hyper.ahajournals.org/content/54/6/1291

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Hypertension can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at: http://www.lww.com/reprints

Subscriptions: Information about subscribing to Hypertension is online at: http://hyper.ahajournals.org//subscriptions/